BCRX Financial Facts
Interest and other income: 109KTotal expenses: 17M
See Full Income Statement
Deferred collaboration revenue: 8.48M
Restricted cash: 1.51M
See Full Balance Sheet
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings
|
Expand Research on BCRX
Next EPS Date | 5/2/24 | EPS Growth Rate | +25.0% |
---|---|---|---|
Average EPS % Beat Rate | +3.6% | Revenue Growth Rate | +26.2% |
Average % Move 1-Wk after EPS | +2.7% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
5/2/24 | Q124 | N/A | -$0.21 | N/A | N/A | $86.31M | N/A | N/A | N/A | ||
2/26/24 | Q423 | -$0.28 | -$0.25 | -$0.03 | $93.4M | $89.97M | N/A | Details | |||
11/2/23 | Q323 | -$0.19 | -$0.25 | +$0.06 | $86.74M | $86.06M | N/A | Details | |||
8/3/23 | Q223 | -$0.24 | -$0.23 | -$0.01 | $81M | $81.41M | N/A | Details | |||
5/3/23 | Q123 | -$0.28 | -$0.30 | +$0.02 | $68.4M | $71.47M | N/A | Details | |||
2/21/23 | Q422 | -$0.38 | -$0.17 | -$0.21 | $79.5M | $75.57M | N/A | Details | |||
11/1/22 | Q322 | -$0.33 | -$0.29 | -$0.04 | $40.99M | $74.62M | N/A | Details | |||
8/4/22 | Q222 | -$0.32 | -$0.34 | +$0.02 | $65.2M | $63.33M | N/A | Details |